Drug Trial Radar · NCT07216079
Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
3
Actual
Start
Oct 15, 2025
Primary completion
Nov 25, 2026
Study completion Nov 25, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Oct 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center, single group, Phase 3 study for treatment with rilzabrutinib. The purpose of this study is to provide continuation of rilzabrutinib treatment to adult participants with ITP who have completed the LTE of the LUNA 3 study in Japan, demonstrating clinically meaningful benefit as judged by the Investigator.
Conditions
- Immune Thrombocytopenia
Interventions
rilzabrutinibDrug
Pharmaceutical form:Tablet-Route of administration:Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- AEs including SAEs and AESIsTime frame: Until study completion, approximately 60 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number: 1001
Tsuchiura, Ibaraki, Japan
Investigational Site Number: 1002
Kanazawa, Ishikawa-ken, Japan
Investigational Site Number: 1003
Iruma-gun, Saitama, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.